Shandong Xinhua Pharmaceutical (SHE:000756, HKG:0719) obtained approval for a clinical trial of its LXH-2103 injection from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.
The LXH-2103 injection was developed by the company to treat moderate to severe postoperative pain.